Abstract: The invention concerns a non-volatile memory element comprising: first and second transistors (106, 108) forming an inverter (104) coupled between a first storage node (112) and an output (110) of the memory element; a third transistor (116) coupled between the first storage node (112) and a first supply voltage (GND, VDD) and comprising a control terminal coupled to said output; a first resistance switching element (102) coupled in series with said third transistor and programmed to have one of first and second resistances (Rmin, Rmax) representing a non-volatile data bit; a fourth transistor (118) coupled between said storage node (112) a second supply voltage (VDD, GND); and control circuitry (130) adapted to activate said third transistor at the start of a transfer phase of said non-volatile data bit to said storage node, and to control said fourth transistor to couple said storage node to said second supply voltage during said transfer phase.

Abstract: A method for automatic detection of defects in TSV vias formed in a layer of semiconductor material, this detection taking place before stacking this layer with a plurality of other layers of semiconductor material for the design of a multilayer chip integrated circuit, comprising: measurement on each of said TSV vias of at least one parameter derived from an electrical characteristic of the TSV vias; detection of defects in said TSV vias according to a comparison of the parameters measured with at least one reference parameter, and calculation of said at least one reference parameter using the measured parameters. The parameter measured on each of the TSV vias comprises an oscillation frequency value derived from a capacitive characteristic of the TSV vias.

Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

Abstract: This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine. The optionally substituted pentofuranonucleoside, or a salt or prodrug thereof, may be administered alone or in combination with one or more optionally substituted pentofuranonucleosides or other anti-viral agents.

Abstract: The présent invention relates to cell-penetrating peptides characterized in that it comprises an amino acid séquence selected in the group consisting of X1LX2RALWX9LX3X9X4LWX9LX5X6X7X8, X1LX2LARWX9LX3X9X4LWX9LX5X6X7X8 and X1LX2ARLWX9LX3X9X4LWX9LX5X6X7X8, wherein X1 is beta-A or S, X2 is F or W, X3 is L, W, C or I, X4 is S, A, N or T, Xs is L or W, X6 is W or R, X7 is K or R, X8 is A or none, and X9 is R or S. Thèse peptides exhibit high efficiency, low toxicity and a natural tropism for lung tissues, and can be used either in simple complex with the cargo to be vectorised, or in nanoparticles comprising two layers of cell-pentrating peptides around the cargo.

Abstract: The present invention relates to a method for the in vitro diagnosis of active tuberculosis, comprising a step of contacting lymphocytes of a patient suspected to have active tuberculosis with at least one protein of mycobacteria, said protein being an enzyme having a lipolytic activity, and a step of detecting the presence of specific activated lymphocytes.

Abstract: A peptide including the amino acids sequence X9CGYX13X14AX16X17X18MX20X21X22X23X24X25X26X27CPLCX32X33, a nucleic acid coding for the peptide, and/or a recombinant vector including the nucleic acid for the preparation of a drug intended for the treatment of cancer.

Abstract: 2? and/or 3? prodrugs of 1?, 2?, 3? or 4?-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.

Abstract: A laser device for emitting waves in a frequency range belonging to the terahertz range, includes the following, in combination: a wave guide extending longitudinally along an axis A-A?; a superconducting coil arranged coaxially to the wave guide and arranged at a first end of the wave guide; a p-Ge p-doped germanium crystal arranged inside the coil such that the turns of the superconducting coil at least partially surround the p-Ge crystal; a cooling device containing a coolant, the superconducting coil and the p-Ge crystal being arranged in the cooling device, and the wave guide partially extending outside the cooling device; and removing the coolant from the wave guide.

Abstract: The invention relates to processes for coating a surface with a crosslinked polyelectrolytes multilayer film incorporating a protein, preferably a growth factor type protein. The invention also relates to crosslinked polyelectrolytes multilayer films obtained by this process, and a coated surface obtained therefrom.

Abstract: The invention concerns a memory device comprising at least one memory cell comprising: first and second pairs of cross-coupled transistors; and a first resistance switching element (202) coupled between a first supply voltage (VDD, GND) and a first transistor of said first pair of transistors and programmed to have one of first and second resistances; and control circuitry adapted to store a data value (DNV) at said first and second storage nodes by coupling said first storage node to said second supply voltage (VDD, GND), the data value being determined by the programmed resistance of the first resistance switching element.

Abstract: The present invention relates to a compound of one of the formulas I to XXI; a pharmaceutical composition comprising at least one such compound; and the use of at least one such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.

Abstract: This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine. The optionally substituted pentofuranonucleoside, or a salt or prodrug thereof, may be administered alone or in combination with one or more optionally substituted pentofuranonucleosides or other anti-viral agents.

Abstract: Derivatized coumarin-based pharmaceutical compositions and methods to use them are provided. The compositions are characterized in that they inhibit the activity of tumor-related CAIX and CAXII to a greater degree than they inhibit the activity of CAI and CAII. The compositions can be used to suppress tumor growth and/or suppress tumor metastases in a mammal.

Abstract: The present invention relates to novel stress-resistant bacteria and the uses thereof. More specifically, the invention relates to isolated stress-resistant bacteria having advantageous properties for the production of organic acids or alcohols in various culture conditions. The invention also relates to methods of producing organic acids or alcohols using said bacteria, particularly from biomass.

Abstract: The invention relates to a process for the hydrolysis-polycondensation of a sterically hindered crosslinkable chromophore, characterized in that the hydrolysis-polycondensation is catalyzed with an acid released by a photoacid generator (PAG).

Abstract: Novel therapeutic compounds for use against Huntington's disease. More especially, an isolated peptide of size less than 100 amino acids and containing: a first sequence having at least 80% identity with sequence AASSG (SEQ ID NO: 1), or a second sequence having at least 80% identity with sequence XAGXDXXTEXPXS (SEQ ID NO: 2), where X designates any amino acid. The use of an isolated peptide of size less than 200 amino acids and containing the sequence(s) defined above, as a drug is also described.

Abstract: The invention relates to compounds of formula (I) wherein the groups A and B represent independently from each other —CH?CH—, or —C?C—, the terms t, u, v, w represent, independently from each other, values ranging from 0 to 9, the groups Y1 and Y2 can represent independently from each other an alkyl group (linear, branched or substituted) carrying from 1 to 9 carbon atoms, the groups Z1, Z2, Z3, and Z4 can represent independently from each other a chemically reactive group W, such as OH, NH2, SH, the groups Z5 and Z6 represent independently from each other a hydrogen atom, silica nanoparticles functionalized by these compounds, and their use as drugs.

Abstract: 2? and/or 3? prodrugs of 1?, 2?, 3? or 4?-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.

Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.